Skip to main
OCUL

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix Inc has demonstrated significant advancements in its regulatory strategy, notably accelerating the NDA submission timelines for its lead product, Axpaxli, by at least one year, potentially leading to an FDA decision as early as 2027. Clinical trials have shown that Axpaxli outperformed control treatments with high statistical significance, which is expected to further enhance its market potential. Additionally, the positive safety profile highlighted by Key Opinion Leaders suggests strong prospects for rapid adoption in clinical settings, reinforcing the company's favorable outlook in the biotechnology sector focused on ophthalmic therapies.

Bears say

Ocular Therapeutix Inc has faced significant investor pressure, as evidenced by a 22% decline in stock price despite meeting the primary endpoint in a clinical trial, indicating a lack of confidence in long-term performance. The company has incurred substantial losses since its inception, raising concerns about its financial sustainability and ability to continue operations without significant capital support. Additionally, increasing market competition from both existing and emerging therapies poses a risk to Ocular's market penetration and pricing strategies, further contributing to the negative outlook.

Ocular Therapeutix (OCUL) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Ocular Therapeutix (OCUL) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.